Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 165 results
Filters: Author is Lalama, Christina M  [Clear All Filters]
Found 165 results.

Adult

Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. "Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects." J. Infect. Dis.. 2008;197(6):867-70.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Gandhi RT, McMahon DK, Bosch RJ, et al. "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation." PLoS Pathog.. 2017;13(4):e1006285.

Anti-HIV Agents

Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Gandhi RT, McMahon DK, Bosch RJ, et al. "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation." PLoS Pathog.. 2017;13(4):e1006285.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Brehm JH, Lalama CM, Hughes MD, et al. "Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2011;56(4):344-8.

Pages